Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
12.99
+1.07 (8.98%)
After Hours: 13.14 +0.15 (1.15%)
Apr 24, 7:57PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.90 - 13.26
52 week 5.99 - 14.28
Open 12.05
Vol / Avg. 3.07M/1.11M
Mkt cap 468.66M
P/E     -
Div/yield     -
EPS -1.32
Shares 36.08M
Beta 1.51
Inst. own 59%
May 21, 2014
Cytokinetics, Inc. Annual Shareholder Meeting - 6:00PM EDT - Add to calendar
May 6, 2014
Q1 2014 Cytokinetics, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Apr 30, 2014
Cytokinetics, Inc. Investor Breakfast and Webcast Following Presentation of Results from BENEFIT-ALS - 7:00AM EDT - Add to calendar
Apr 8, 2014
Cytokinetics, Inc. at Needham Healthcare Conference - Webcast
Mar 10, 2014
Cytokinetics, Inc. at ROTH Conference - Webcast
Mar 3, 2014
Cytokinetics, Inc. at Cowen Health Care Conference - Webcast
Feb 24, 2014
Cytokinetics, Inc. at Canaccord Genuity Orphan Drug One-on-One Day
Feb 12, 2014
Cytokinetics, Inc. at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Cytokinetics, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
Feb 6, 2014
Q4 2013 Cytokinetics, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 26.82% -110.01%
Operating margin 26.42% -110.59%
EBITD margin - -109.18%
Return on average assets 30.60% -41.95%
Return on average equity 55.62% -54.15%
Employees 85 -
CDP Score - -

Address

280 East Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company�s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.

Officers and directors

L.Patrick Gage Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Fady I. Malik M.D., Ph.D. Senior Vice President - Research and Early Development
Age: 49
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Clinical Research and Development, Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Santo J. Costa Independent Director
Bio & Compensation  - Reuters
Denise M. Gilbert Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John T. Henderson M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
B. Lynne Parshall Esq. Independent Director
Age: 57
Bio & Compensation  - Reuters